Cita APA (7a ed.)
Peng, X., He, X., Zhang, W., Huang, H., Li, X., Chen, J., . . . Song, X. (2024 Supplement). Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial. Journal of Clinical Oncology, 42, 139-159.
Cita Chicago Style (17a ed.)
Peng, Xingchen, Xuan He, Weiwei Zhang, Hai Huang, Xue Li, Jie Chen, Yuquan Wei, y Xiangrong Song. "Safety, Tolerability, and Immunogenicity of WGc-043 in Subjects with EBV-positive Cancers: Results from an Investigator-initiated Trial." Journal of Clinical Oncology 42 (2024 Supplement): 139-159.
Cita MLA (9a ed.)
Peng, Xingchen, et al. "Safety, Tolerability, and Immunogenicity of WGc-043 in Subjects with EBV-positive Cancers: Results from an Investigator-initiated Trial." Journal of Clinical Oncology, vol. 42, 2024 Supplement, pp. 139-159.
Precaución: Estas citas no son 100% exactas.